Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.
Epistemonikos ID: 20d825530d37d458cfc698403f0f00fb9266ffe2
First added on: Oct 01, 2026